| 31.05 08:10 | US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert |
| 31.05 07:29 | dpa-AFX: Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients |
| 31.05 07:19 | dpa-AFX: Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month |
| 31.05 07:04 | dpa-AFX: *REGENERON: FDA EXTENDS TARGET ACTION DATE OF SBLA FOR DUPIXENT FOR COPD PATIENTS WITH TYPE 2 INFLAMMATION BY THREE MONTHS |
| 13.05 12:37 | FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig |
| 13.05 07:56 | dpa-AFX: Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis |
| 13.05 07:39 | dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS |
| 02.05 13:31 | dpa-AFX: Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates |
| 02.05 12:44 | dpa-AFX: *REGENERON Q1 GAAP NET INCOME $722 MLN; NON-GAAP NET INCOME $1.12 BLN |
| 02.05 12:44 | dpa-AFX: *REGENERON Q1 REVENUES DOWN 1% TO $3.15 BLN |
| 02.05 12:37 | dpa-AFX: *REGENERON PHARMA Q1 GAAP EPS $6.27 AND NON-GAAP EPS $9.55 |
| 25.03 12:46 | dpa-AFX: Regeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular Lyphoma |
| 25.03 12:13 | dpa-AFX: *REGENERON: FDA ISSUES CRLS FOR ODRONEXTAMAB BLA IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA AND R/R DIFFUSE LARGE B-CELL LYMPHOMA |
| 11.03 12:33 | dpa-AFX: Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8 |
| 11.03 12:15 | dpa-AFX: *REGENERON PHARMA: FDA APPROVES PRALUENT INJECTION TO TREAT CHILDREN WITH GENETIC FORM OF HIGH CHOLESTEROL |
| 23.02 07:36 | dpa-AFX: Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation |
| 21.02 13:50 | dpa-AFX: Regeneron: Linvoseltamab BLA To Treat RR/MM Accepted For FDA Priority Review |
| 21.02 13:12 | dpa-AFX: *REGENERON PHARMA: FDA ACCEPTS FOR PRIORITY REVIEW BLA FOR LINVOSELTAMAB FOR TREATMENT OF R/R MULTIPLE MYELOMA |
| 16.02 07:36 | dpa-AFX: Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment |
| 06.02 12:33 | dpa-AFX: *DZ BANK RAISES FW FÜR REGENERON PHARMACEUTICALS TO 1068 (915) USD - 'BUY' |
|
|
